NCT03741426 (WIRE) is a Phase 2 clinical trial of Olaparib in Renal Cell Cancer, sponsored by CCTU- Cancer Theme.

Who is sponsoring NCT03741426?

NCT03741426 is sponsored by CCTU- Cancer Theme.

What drugs are being tested in NCT03741426?

Interventions in NCT03741426: Olaparib, Cediranib, Durvalumab.

What condition does NCT03741426 study?

NCT03741426 studies Renal Cell Cancer.

Is NCT03741426 still recruiting?

NCT03741426 is currently status unknown. Last updated 7 June 2023.

Last reviewed 2023-06-07 · How we verify

NCT03741426: WIRE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

WIRE - Novel Treatments in Renal Cell Cancer

Status unknown Phase 2 Last updated 7 June 2023

What this trial tests

Phase 2 trial testing Olaparib in Renal Cell Cancer in 60 participants. Status unknown.

Timeline

27 July 2020

Primary endpoint
30 November 2025

30 November 2025

Quick facts

Lead sponsor	CCTU- Cancer Theme
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	basic science
Enrollment	60
Start date	27 July 2020
Primary completion	30 November 2025
Estimated completion	30 November 2025
Sites	2 locations across United Kingdom

Drugs / interventions tested

Olaparib (olaparib) — full drug profile →
Cediranib — full drug profile →
Durvalumab — full drug profile →

Conditions studied

Renal Cell Cancer — all drugs for Renal Cell Cancer →

Sponsor

CCTU- Cancer Theme — full company profile →

Who can join

18 and older, any sex, with Renal Cell Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation of proof of mechanism with relation to ktrans and/or CD8 count when 3 different IMPs are given as monotherapy or as combination therapy. These would be administered in the "window of opportunity", prior to nephrectomy in surgically resectable renal cell cancer

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy.
Shi C, Qin K, Lin A, Jiang A, et al · · 2022 · cited 60× · PMID 36071479 · DOI 10.1186/s13046-022-02469-0
Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications.
Sun W, Zhang Q, Wang R, Li Y, et al · · 2021 · cited 44× · PMID 34026622 · DOI 10.3389/fonc.2021.648687
The potential of PARP inhibitors in targeted cancer therapy and immunotherapy.
Hunia J, Gawalski K, Szredzka A, Suskiewicz MJ, et al · · 2022 · cited 25× · PMID 36533080 · DOI 10.3389/fmolb.2022.1073797
The Frontline Immunotherapy-Based Treatment of Advanced Clear Cell Renal Cell Carcinoma: Current Evidence and Clinical Perspective.
Kim IH, Lee HJ. · · 2022 · cited 18× · PMID 35203461 · DOI 10.3390/biomedicines10020251
Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology.
Shah SM, Demidova EV, Lesh RW, Hall MJ, et al · · 2022 · cited 16× · PMID 35051883 · DOI 10.1016/j.ctrv.2021.102337
PD-1/PD-L1 inhibitors-based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies.
Ding L, Dong HY, Zhou TR, Wang YH, et al · · 2021 · cited 15× · PMID 34382349 · DOI 10.1002/cam4.4190
The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocol.
Ursprung S, Mossop H, Gallagher FA, Sala E, et al · · 2021 · cited 13× · PMID 34794412 · DOI 10.1186/s12885-021-08965-4
Three-Dimensional Printed Molds for Image-Guided Surgical Biopsies: An Open Source Computational Platform.
Crispin-Ortuzar M, Gehrung M, Ursprung S, Gill AB, et al · · 2020 · cited 13× · PMID 32804543 · DOI 10.1200/cci.20.00026

Verify or expand the search:

Other trials of Olaparib

Trials testing the same drug.

NCT05522491 — Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Br · Phase 2 · not yet recruiting
NCT05128734 — Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) · Phase 2 · not yet recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07407452 — Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Che · Phase 2 · not yet recruiting
NCT06915025 — Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemo · Phase 3 · recruiting

Other recruiting trials for Renal Cell Cancer

Currently open trials in the same condition.

NCT07294859 — Contrast-enhanced Ultrasound and Super-resolution Imaging Predict Renal Function Outcome After Nephrectomy · recruiting
NCT06903312 — Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations. · Phase 4 · recruiting
NCT07020169 — Using 3D Kidney Model Based on Artificial Intelligence to Assist Partial Nephrectomy: A Prospective Validation Study · NA · recruiting
NCT06714916 — Optimising Renal Tumour Management Through Artificial Intelligence Modules · recruiting
NCT06751498 — The Value of a Convolutional Neural Network-Based Renal Artery Perfusion Model in Predicting Renal Function After Partia · recruiting

Other CCTU- Cancer Theme trials

Trials by the same sponsor.

NCT04761146 — A Safety and Efficacy Study of Intra-tumoural Diffusing Alpha Radiation Emitters for the Treatment of Vulva Cancer · NA · unknown
NCT05097378 — Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma · Phase 2 · unknown
NCT04285242 — Metabolic and Immunological Phenotyping in Patients With Cancer · unknown
NCT04107168 — Microbiome Immunotherapy Toxicity and Response Evaluation · unknown
NCT04326387 — Evaluation of Novel Diagnostic Tests for COVID-19 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03741426 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CCTU- Cancer Theme
Last refreshed: 7 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03741426.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing